S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

CV Sciences Stock Forecast, Price & News

-0.01 (-6.25%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
939,956 shs
Average Volume
528,980 shs
Market Capitalization
$16.77 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CVSI News and Ratings via Email

Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter.

CV Sciences logo

About CV Sciences

CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharmaceutical segments. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol products through the PlusCBD brand. The Specialty Pharmaceutical segment focuses on developing cannabinoids to treat medical indications. The company was founded by H. J. Cole, Michael J. Mona, Jr. and Michael J. Mona III on December 9, 2010 and is headquartered in San Diego, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$24.43 million
Book Value
$0.10 per share


Net Income
$-22.28 million
Pretax Margin




Free Float
Market Cap
$16.77 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

1.48 out of 5 stars

Analyst Opinion: 3.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions

Is CV Sciences a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CV Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVSI, but not buy additional shares or sell existing shares.
View analyst ratings for CV Sciences
or view top-rated stocks.

How has CV Sciences' stock been impacted by Coronavirus?

CV Sciences' stock was trading at $0.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CVSI stock has decreased by 75.0% and is now trading at $0.15.
View which stocks have been most impacted by COVID-19

How were CV Sciences' earnings last quarter?

CV Sciences, Inc. (OTCMKTS:CVSI) issued its earnings results on Thursday, August, 12th. The company reported ($0.03) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.03). The firm had revenue of $5.13 million for the quarter, compared to analyst estimates of $5.12 million. CV Sciences had a negative trailing twelve-month return on equity of 144.40% and a negative net margin of 78.86%.
View CV Sciences' earnings history

What price target have analysts set for CVSI?

3 Wall Street analysts have issued 1 year price targets for CV Sciences' shares. Their forecasts range from $0.50 to $0.65. On average, they anticipate CV Sciences' share price to reach $0.58 in the next year. This suggests a possible upside of 288.9% from the stock's current price.
View analysts' price targets for CV Sciences
or view top-rated stocks among Wall Street analysts.

Who are CV Sciences' key executives?

CV Sciences' management team includes the following people:
  • Joseph D. Dowling, Chief Executive Officer, Secretary & Director
  • Joerg Grasser, Chief Financial Officer
  • Tim Hitchman, Operations Director
  • Shane Hart, Senior Vice President-Marketing

What other stocks do shareholders of CV Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Charlotte's Web (CWBHF), KushCo (KSHB), (APHA), OrganiGram (OGI), GW Pharmaceuticals (GWPH), Tilray (TLRY) and Medical Marijuana (MJNA).

What is CV Sciences' stock symbol?

CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."

How do I buy shares of CV Sciences?

Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CV Sciences' stock price today?

One share of CVSI stock can currently be purchased for approximately $0.15.

How much money does CV Sciences make?

CV Sciences has a market capitalization of $16.77 million and generates $24.43 million in revenue each year. The company earns $-22.28 million in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does CV Sciences have?

CV Sciences employs 94 workers across the globe.

What is CV Sciences' official website?

The official website for CV Sciences is www.cvsciences.com.

Where are CV Sciences' headquarters?

CV Sciences is headquartered at 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121.

How can I contact CV Sciences?

CV Sciences' mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at (866) 290-2157, via email at [email protected], or via fax at 619-876-4321.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.